You are here

Crohn’s Disease Market Set to Record Exponential Growth by 2021 – Persistence Market Research – Medgadget (blog)

Crohn’s Disease Market Set to Record Exponential Growth by 2021 – Persistence Market ResearchMedgadget (blog)Crohn’s disease refers to long term inflammatory bowel disease, which causes inflammation of the lining of the digestive tract. It affects the large and small intestine and is generally diagnosed in persons within the age group of 20-29. It can have … FULL ARTICLE: http://zpr.io/PytHM

Read More

High-dose mesalamine effective as alternative induction therapy for mild-to-moderate Crohn’s disease

Among different induction therapies for mild-to-moderate Crohn’s disease, corticosteroids and high-dose budesonide were both effective, and high-dose mesalamine was an effective alternative, according to the results of a Bayesian network meta-analysis.“Physicians and patients have many options in treating mild to moderately active Crohn’s disease,” Gilaad G. Kaplan, MD, MPH, from the departments of medicine and community health sciences at University of Calgary in Canada, told Healio Gastroenterology. “While corticosteroids are effective in treating Crohn’s disease, patients often prefer to avoid prednisone due to potential systemic toxicities.” FULL ARTICLE: http://zpr.io/Pytti

Read More

UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care.

Related Articles UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care. Gut. 2017 Feb 21;: Authors: Brooks AJ, Smith PJ, Cohen R, Collins P, Douds A, Forbes V, Gaya DR, Johnston BT, McKiernan PJ, Murray CD, Sebastian S, Smith M, Whitley L, Williams L, Russell RK, McCartney SA, Lindsay JO Abstract The risks of poor transition include delayed and inappropriate transfer that can result in disengagement with healthcare. Structured transition care can improve control of chronic digestive diseases and long-term health-related…

Read More

Increased expression of IL12B mRNA transcribed from the risk haplotype for Crohn’s disease is a risk factor for disease relapse in Japanese patients.

Related Articles Increased expression of IL12B mRNA transcribed from the risk haplotype for Crohn’s disease is a risk factor for disease relapse in Japanese patients. J Gastroenterol. 2017 Feb 22;: Authors: Kakuta Y, Kimura T, Negoro K, Kuroha M, Shiga H, Endo K, Kinouchi Y, Shimosegawa T Abstract BACKGROUND: IL12B is a promising candidate for a susceptibility gene in Crohn’s disease (CD). The aim of this study was to perform a candidate gene analysis of IL12B in Japanese CD patients, investigate whether the genotype is associated with disease phenotypes, and…

Read More

The incidence of inflammatory bowel disease in Denmark 1980-2013: a nationwide cohort study.

Related Articles The incidence of inflammatory bowel disease in Denmark 1980-2013: a nationwide cohort study. Aliment Pharmacol Ther. 2017 Feb 23;: Authors: Lophaven SN, Lynge E, Burisch J Abstract BACKGROUND: Globally, the incidence rates of inflammatory bowel disease (IBD) are increasing; however, data from high-incidence areas are conflicting. Previous studies in Denmark have assessed incidence rates of Crohn’s disease (CD) and ulcerative colitis (UC) using short observation periods. AIM: To investigate trends in IBD incidence in Denmark over a thirty-year period using nationwide data. METHODS: Patients diagnosed with CD or…

Read More

Epidemiology of inflammatory bowel disease among participants of the Millennium Cohort: incidence, deployment-related risk factors, and antecedent episodes of infectious gastroenteritis.

Epidemiology of inflammatory bowel disease among participants of the Millennium Cohort: incidence, deployment-related risk factors, and antecedent episodes of infectious gastroenteritis. Aliment Pharmacol Ther. 2017 Feb 23;: Authors: Porter CK, Welsh M, Riddle MS, Nieh C, Boyko EJ, Gackstetter G, Hooper TI Abstract BACKGROUND: Crohn’s disease (CD) and ulcerative colitis (UC) are two pathotypes of inflammatory bowel disease (IBD) with unique pathology, risk factors and significant morbidity. AIM: To estimate incidence and identify IBD risk factors in a US military population, a healthy subset of the US population, using information…

Read More

Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.

Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Feb 23;: Authors: Strik AS, van den Brink GR, Ponsioen C, Mathot R, Löwenberg M, D’Haens GR Abstract BACKGROUND: Loss of response to anti-tumour necrosis factor (TNF) therapy in patients with inflammatory bowel disease (IBD) is often caused by anti-drug antibody formation with neutralisation of drug effect. Addition of an immunomodulator has been suggested to reduce immunogenicity, leading to regained response. AIM: To investigate whether addition…

Read More

Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis.

Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2017 Feb 22;: Authors: Shah ED, Farida JP, Siegel CA, Chong K, Melmed GY Abstract BACKGROUND: The overall risk for infection with contemporary biological agents in treating Crohn’s disease (CD) and ulcerative colitis (UC) has not been systematically assessed. METHODS: We performed a PubMed and Cochrane database literature search to evaluate randomized, placebo-controlled trials of biologics in treating UC and CD. Meta-analysis was performed using a DerSimonian and Laird random…

Read More

Anti-TNFα Treatment After Surgical Resection for Crohn’s Disease Is Effective Despite Previous Pharmacodynamic Failure.

Anti-TNFα Treatment After Surgical Resection for Crohn’s Disease Is Effective Despite Previous Pharmacodynamic Failure. Inflamm Bowel Dis. 2017 Feb 22;: Authors: Assa A, Bronsky J, Kolho KL, Zarubova K, de Meij T, Ledder O, Sladek M, van Biervliet S, Strisciuglio C, Shamir R Abstract BACKGROUND: The outcome of patients with Crohn’s disease who failed anti-tumor necrosis factor alpha (anti-TNFα) therapy despite adequate serum drug levels (pharmacodynamic failure) is unclear. We aimed to assess such pediatric patients who underwent intestinal resection and were re-treated with the same anti-TNFα agent postoperatively. METHODS:…

Read More
<< Go Back